Novel nicotinamide adenine dinucleotide analogues as potential anticancer agents: Quest for specific inhibition of inosine monophosphate dehydrogenase

Krzysztof W. Pankiewicz

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations

Abstract

Synthetic nicotinamide adenine dinucleotide (NAD) analogues containing 5-β-D-ribofuranosylnicotinamide (C-NAD), 6-β-D-ribofuranosylpicolinamide (C-PAD), 3-β-D-ribofuranosylbenzamide (BAD), and 2-β-D- ribofuranosylthiazole-4-carboxamide (TAD) in place of the nicotinamide riboside moiety are described and evaluated as potential inhibitors of inosine monophosphate dehydrogenase (IMPDH). TAD and BAD showed potent inhibitory activity against the enzyme in the form of pyrophosphates, as well as metabolically stable methylene- and difluoromethylenebis(phosphonate)s. Fluorination at the C2' (ribo and arabino configuration) and C3' (ribo) of the adenosine moiety of TAD afforded analogues highly potent against IMPDH, but weakly active against alcohol dehydrogenase. With the exception of the methylenebis(phosphonate) analogue of TAD compounds containing a methylene bridge were poor inhibitors of growth of K562 cells. On the other hand, NAD analogues containing difluoromethylene linkage were highly effective in inhibition of K562 cell growth, as well as potent inducers of K562 cell differentiation. Such compounds, therefore, may be of potential therapeutic interest.

Original languageEnglish (US)
Pages (from-to)89-100
Number of pages12
JournalPharmacology and Therapeutics
Volume76
Issue number1-3
DOIs
StatePublished - Nov 1 1997

Keywords

  • Anticancer
  • IMPDH inhibitors
  • NAD analogues

Fingerprint Dive into the research topics of 'Novel nicotinamide adenine dinucleotide analogues as potential anticancer agents: Quest for specific inhibition of inosine monophosphate dehydrogenase'. Together they form a unique fingerprint.

Cite this